Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.60 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.60 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL8698827 | 0.91 | HMGCR (0.78) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL8698824 | 0.90 | HMGCR (0.77) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL14472019 | 0.83 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL3014 | 0.83 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL3013 | 0.83 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL5598406 | 0.83 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL27522597 | 0.83 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2175991 | 0.83 | HMGCR (0.98) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL6943019 | 0.82 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL6317379 | 0.82 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240175032-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | SIRNAOMICS, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4359377-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-05-01 | — | — | EP | disclosed |
| EP-4347823-A1 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230104125-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230068339-A1 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230019098-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | RISEN (SHANGHAI) MEDICINAL TECH CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20230002772-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-01-05 | — | — | US | disclosed |
| WO-2022266753-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-12-29 | — | — | WO | disclosed |
| EP-4107265-A1 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022256395-A1 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2010148013-A2 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| EP-2245039-A2 | OPTIMIZED METHODS FOR DELIVERY OF DSRNA TARGETING THE PCSK9 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010099341-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MIG-12 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100010066-A1 | Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene | ALNYLAM PHARMACEUTICALS, INC. | 2010-01-14 | — | — | US | disclosed |
| WO-2009134487-A2 | OPTIMIZED METHODS FOR DELIVERY OF DSRNA TARGETING THE PCSK9 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| EP-1799263-A4 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | HARVARD COLLEGE (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2001484-A2 | METHODS AND COMPOSITIONS FOR TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | The President and Fellows of Harvard College (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007111992-A2 | METHODS AND COMPOSITIONS FOR TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1799263-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | The President and Fellows of Harvard College (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006031931-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230068339-A1 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | APOB, RNASE1, APOL1 | HMGCR 62/4885ALOX15 2424/4885SLCO1B1 4087/4885 |
| US-20230104125-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | PCSK9, PCSK7, PCSK6 | HMGCR 13/4885ALOX15 781/4885SLCO1B1 4371/4885 |
| US-20240175032-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | PCSK9, PCSK6, LDLR | HMGCR 24/4885ALOX15 1300/4885SLCO1B1 3653/4885 |
| US-20230002772-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PCSK9, LDLR, RNASE1 | HMGCR 15/4885ALOX15 2551/4885SLCO1B1 4315/4885 |
| US-20230019098-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | PLK1, BRDT, BCR | HMGCR 1923/4885ALOX15 3690/4885SLCO1B1 3517/4885 |
| US-20100010066-A1 | Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene | PCSK9, PCSK7, PCSK6 | HMGCR 167/4885ALOX15 2098/4885SLCO1B1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.